Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. It targets molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.